Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
33rd Annual J.P. Morgan Healthcare Conference (Live)
01/12/15 at 2:30 p.m. PT
33rd Annual J.P. Morgan Healthcare Conference
Monday, January 12, 2015 2:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 2.07 (3.60%)
Data as of 12/18/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
12/16/14Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1
ISIS-DMPK Rx Extends the Targeting of Antisense Drugs to Include Muscle Tissue CARLSBAD, Calif., Dec. 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1).  DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells.  ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA. "... 
Printer Friendly Version
12/07/14Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014 CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic e... 
Printer Friendly Version
12/05/14Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
CARLSBAD, Calif., Dec. 5, 2014 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide. Dr. Crooke was selected for the lifetime achievement award by an independent panel of global life sciences experts, based on Dr. Crooke's dedication to advancing... 
Printer Friendly Version
12/03/14ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
Substantial reductions of up to 86% in triglycerides observed All patients achieved a triglyceride level <500 mg/dL during study First study to support the role of apoC-III as a key regulator of triglyceride metabolism utilizing multiple pathways CARLSBAD, Calif., Dec. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS) were published in The New Engl... 
Printer Friendly Version
Upcoming EventsMore >>
01/12/15 2:30 p.m. PT
33rd Annual J.P. Morgan Healthcare Conference
LocationSan Francisco, CA
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.


Receive Isis alerts in your email.

Sign Up